Efficacy of selinexor combined with subcutaneous decitabine in myeloid malignancies refractory to or relapsed after venetoclax therapy
10.3760/cma.j.cn121090-20240920-00358
- VernacularTitle:塞利尼索联合皮下注射地西他滨治疗既往维奈克拉治疗失败的髓系恶性肿瘤疗效分析
- Author:
Ruihua MI
1
;
Lin WANG
;
Ning HU
;
Chao LI
;
Lin CHEN
;
Yixuan MA
;
Xudong WEI
Author Information
1. 郑州大学附属肿瘤医院/河南省肿瘤医院，郑州 450000
- Publication Type:Journal Article
- From:
Chinese Journal of Hematology
2025;46(5):473-477
- CountryChina
- Language:Chinese
-
Abstract:
Venetoclax (Ven) is now widely used for both acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS), yet there is no consensus on salvage regimens after Ven failure. This study retrospectively evaluated the efficacy and safety of selinexor combined with subcutaneous decitabine (DAC) in 10 patients with AML or MDS with excess blasts (MDS-EB1/2) who had experienced prior Ven treatment failure. A literature review was also performed. Among the 7 patients with AML, 1 achieved complete remission (CR), 2 achieved CR with incomplete hematologic recovery (CRi), 1 achieved partial remission (PR), 2 had no remission, and 1 experienced disease progression (PD). Among the 3 patients with MDS, 2 achieved marrow CR and 1 had stable disease (SD). The median duration of response among the 6 responding patients was 2 months (range, 0.5-6 months). All 10 patients experienced varying degrees of myelosuppression. Five patients had mild gastrointestinal reactions, all of which were manageable. The overall tolerability was good, and no treatment-related deaths occurred. These findings suggest that selinexor combined with subcutaneous decitabine offers a novel and well-tolerated therapeutic option for patients with myeloid malignancies who have previously failed venetoclax-based therapy.
